Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab’)₂ and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma

References

• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.
   PubMed Web of Science ®Google Scholar
• Balogh J, Victor III D, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53
   PubMed Web of Science ®Google Scholar
• Colagrande S, Inghilesi AL, Aburas S, et al. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22:7645–7659.
   PubMed Web of Science ®Google Scholar
• Kamaly N, Yameen B, Wu J, et al. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116:2602–2663.
   PubMed Web of Science ®Google Scholar
• Bogart LK, Pourroy G, Murphy CJ, et al. Nanoparticles for imaging, sensing and therapeutic intervention. ACS Nano. 2014;8:3107–3122
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, et al. Nanoparticles in oncology: the new theragnostic molecules. Anticancer Agents Med Chem. 2011;11:669–686.
   PubMed Web of Science ®Google Scholar
• Chen H, Gao J, Lu Y, et al. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release. 2008;128:209–216.
   PubMed Web of Science ®Google Scholar
• Liu D, Yang F, Xiong F, et al. The smart drug delivery system and its clinical potential. Theranostics. 2016;6:1306–1323.
   PubMed Web of Science ®Google Scholar
• Bernabeu E, Cagel M, Lagomarsino E, et al. Paclitaxel: what has been done and the challenges remain ahead. Int J Pharm. 2017;526:474–495.
   PubMed Web of Science ®Google Scholar
• Geng CX, Zeng ZC, Wang JY. Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol. 2003;9:696–700.
   PubMed Web of Science ®Google Scholar
• Jin C, Li H, He Y, et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol. 2010;136:267–274.
   PubMed Web of Science ®Google Scholar
• Iesalnieks I, Tange S, Scherer MN, et al. Paclitaxel promotes liver graft survival in rats and inhibits hepatocellular carcinoma growth in vitro and is a potentially useful drug for transplant patients with liver cancer. Transplant Proc. 2002;34:2316–2317.
   PubMed Web of Science ®Google Scholar
• Ai D, Guan Y, Liu XJ, et al. Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer. Onco Targets Ther. 2016;9:5693–5698.
   PubMed Web of Science ®Google Scholar
• Jin C, Yang Z, Yang J, et al. Paclitaxel-loaded nanoparticles decorated with anti-CD133 antibody: a targeted therapy for liver cancer stem cells. J Nanopart Res. 2014;16:2157–2171.
   Web of Science ®Google Scholar
• Xu J, Xu HY, Zhang Q, et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res. 2007;5:605–614.
   PubMed Web of Science ®Google Scholar
• Jin C, Qian N, Zhao W, et al. Improved therapeutic effect of DOX–PLGA–PEG micelles decorated with bivalent fragment HAb18 F(ab’)2 for hepatocellular carcinoma. Biomacromolecules. 2010;11:2422–2431.
   PubMed Web of Science ®Google Scholar
• Svensen N, Walton JG, Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol Sci. 2012;33:186–192.
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release. 2016;229:130–139.
   PubMed Web of Science ®Google Scholar
• Kanwar JR, Gibbons J, Verma AK, et al. Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide. Anticancer Drugs. 2012;23:471–482.
   PubMed Web of Science ®Google Scholar
• Da Silva CG, Rueda F, Löwik CW, et al. Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials. 2016;83:308–320
   PubMed Web of Science ®Google Scholar
• Mcdonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62:5381–5385.
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732–6740.
   PubMed Web of Science ®Google Scholar
• Jin C, Bai L, Wu H, et al. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res. 2009;26:1776–1784.
   PubMed Web of Science ®Google Scholar
• Jin C, Bai L, Wu H, et al. Radiosensitization of paclitaxel, etanidazole and paclitaxel + etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials. 2007;28:3724–3730.
   PubMed Web of Science ®Google Scholar
• Kohn S, Nagy JA, Dvorak HF, et al. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest. 1992;67:596–607.
   PubMed Web of Science ®Google Scholar
• Wesselinova D. Current major cancer targets for nanoparticle systems. Curr Cancer Drug Targets. 2011;11:164–183.
   PubMed Web of Science ®Google Scholar
• Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med. 2012;18:385–393.
   PubMed Web of Science ®Google Scholar
• Kristensen M, Nielsen HM. Cell-penetrating peptides as carriers for oral delivery of biopharmaceuticals. Basic Clin Pharmacol Toxicol. 2016;118:99–106.
   PubMed Web of Science ®Google Scholar